Elacres RAD1901 ELAC-ESTRANT ELC-001伊拉曲班.艾拉司群，艾拉司琼
Elacestrant 345mg

Elacestrant

Another Name
Elacres RAD1901 ELAC-ESTRANT ELC-001伊拉曲班， 艾拉司群，艾拉司琼
Indications
human epidermal growth factor receptor 2-negative (HER2-) breast cancer
Reg No
09 L 1197/24 09 L 1193/24
Inspection No
2127-24 2122-24
dosage form:pills
Specs:86mg*30pills
Indate:2 Years
Date：2024-10-19 Views：1366
Drug Info

COMPOSITION:

  • Each film-coated tablet contains Elacestrant dihydrochloride 100mg equivalent to Elacestrant…………………………………. 86mg.
  • Each film-coated tablet contains Elacestrant dihydrochloride 100mg equivalent to Elacestrant…………………………………. 345mg.

INDICATION:

LuciElace is an estrogen receptor antagonist indicated for:

• treatment of postmenopausal women or adult men, with ERpositive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.

DOSAGE AND USE:

• Select patients for treatment with LuciElace based on the presence of ESR1 mutations.

• The recommended dosage of LuciElace is one 345 mg, once daily, with food.

• Dose interruption, reduction, or permanent discontinuation may be required due to adverse reactions.

STORAGE:

In a dry place and store at 20℃ to 25℃.

MANUFACTURED AND MARKETED BY:

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING:

Keep medicine out of reach of Children. Do not administer LuciElace during Pregnancy and Lactation.

Original article, if reprinted, please indicate the link to this article: https://lucius-pharmaceuticals.com/drug/elacestrant/

Related News